ANGEL & VC FUNDING
Mid Atlantic Bio Angels group (MABA), is an angel investor group focused exclusively on new and emerging life science companies. Membership in MABA is by invitation only, and is extended to active, accredited investors (life science angels) who wish to make investments in life science companies, as well as institutional investors and life science company venture arms wishing to invest alongside the angels.
1st Pitch has been organized by MABA (Mid Atlantic Bio Angels, a life science investor group, to encourage and educate aspiring life science entrepreneurs who know they may be too early to seek investment but want the opportunity to practice their pitch and to receive constructive criticism from experienced and knowledgeable professionals.
Monthly pitch events with audience of angel investors, family offices, foundations, & early-stage funds. Encourage for-profit social ventures and early-stage companies. IC investors do not consider applications from:
- Individuals, projects or technologies - only fully formed companies
- Businesses that are in concept-stage only
- Companies that are religion-based
- Purely non-profit organizations (We will accept applications from for-profit subsidiaries or partners of non-profits)
- Venture funds
Members collaborate on due diligence but make individual investments. Have monthly educational breakfasts.
Active network of 330+ angel investors and startup enthusiasts supporting companies founded or led by Cornell alumni, students or faculty.
Venture Capitalist (NOTE: not an exhaustive list)
Primers and guides to venture capital funding put out by law firms:
HGP seeks to identify and invest in emerging companies with high growth potential. We seek to invest with seasoned entrepreneurs building emerging growth stage companies with defensible positions in large and growing markets. HGP typically invests $3.0 million to $7.0 million initially and continues to invest and build value through the growth of our portfolio companies. We typically seek board representation in our investments and provide constructive, strategic, operating and networking support to our portfolio companies. We concentrate our investment focus on opportunities that, in our view, demonstrate the following characteristics (among others): Healthcare IT, Healthcare Services, and Medical Devices/Technology.
- Focus: Start-ups that have licensed intellectual property from a Partner University (includes Columbia University)
- Industry Focus: Life Science: BioPharma, Healthcare IT, Medical Devices & Diagnostics, Tech-Enabled Services
- Stage: Seed, Early, Mature
- Investment Size: Up to $5-10 million over the life of an investment
- Investment Structure: Typically co-invest alongside other venture firms
With $650 million under management, De Novo has made more than 40 investments in medical devices and biotechnology across three funds. We invest in all stages of enterprise development and growth – from early stage to late stage. Our unique background of leading companies as entrepreneurs and operating executives from start to exit enables us to advise entrepreneurs and management teams over the full life cycle of the company.
Since 1981, USVP has invested over $2.7 billion in more than 450 companies. We continue to invest consistently, through good and bad times, taking a long view to building corporate value. Many extremely valuable companies are created during periods when venture investing is out of favor. We invest primarily in information technology and health care, though we are always open to disruptive ideas in other domains. Our decision-making is driven by major industry and global trends, among them:.
- Consumer demand leading IT innovation
- Aging of our population
- Rising cost of health care
- Epidemic of diet-engendered disease
Invests in the development of seed and early stage advanced tech companies
Resources, investment, and guidance for Healthcare and tech innovations to early-stage companies